MINE (chemotherapy)

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

MINE in the context of chemotherapy is an acronym for one of the chemotherapy regimens used for treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.

Today this regimen is often combined with monoclonal antibody rituximab. In this case the regimen is called R-MINE or MINE-R.

The [R]-MINE regimen consists of:

  1. (R)ituximab - anti-CD20 monoclonal antibody that can kill both normal CD20-expressing B cells and malignant ones;
  2. (M)esna to prevent the development of hemorrhagic cystitis which may otherwise result from ifosfamide administration;
  3. (I)fosfamide - an alkylating antineoplastic agent from oxazafosforine group;
  4. (N)ovantrone - a synthetic antracycline analogue (antraquinone) that is able to intercalate DNA and thus prevent cell division (mitosis);
  5. (E)toposide - a topoisomerase inhibitor.[1][2]

Dosing regimen[edit]

Drug Dose Mode Days
(R)ituximab 375 mg/m2 IV infusion Day 1
(M)esna 1330 mg/m2 IV infusion over 1h together with ifosfamide, plus 500 mg PO 4h after ifosfamide Days 1-3
(I)fosfamide 1330 mg/m2 IV infusion over 1h Days 1-3
(N)ovantrone 8 mg/m2 IV infusion Day 1
(E)toposide 65 mg/m2 IV infusion over 1h Days 1-3